Aclaris Therapeutics, Inc. (ACRS) analyst actions
Rating and price-target actions on ACRS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ACRS overview →
4 measured ACRS analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052 | Press release | +1.53% | +2.75% | |
| Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 | Press release | -1.53% | +1.92% | |
| Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 | Press release | -2.74% | -4.79% | |
| Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | Press release | +3.74% | -2.04% |
Keep exploring
More ACRS: earnings → · SEC filings → · ACRS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 281 | -0.51% | 36% |
| Anika Therapeutics Inc. (ANIK) | 280 | +0.05% | 51% |
| Coherus Oncology, Inc. (CHRS) | 280 | +0.21% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.